Alizyme

CompanyUnited Kingdom

Alizyme develops one asset, in phase 2, no development reported (cetilistat in obesity). Mostly small molecule acting on LIPF and PNLIP; based in the United Kingdom.

1
Asset
Furthest stage
Phase 2, no development reported
3
Trials
0
Signals

Pipeline

1
  • cetilistat

    Inhibits gastrointestinal lipases, reducing dietary fat absorption and increasing fecal fat excretion.

    Phase 2, no development reported, Small molecule, LIPF, PNLIP, obesity, type 2 diabetes

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials3
  • Similar companies6

Intelligence